SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

05 Aug 2025 Evaluate
A decent increase of about 26.70% in the sales to Rs. 5786.40 millions was observed for the quarter ended June 2025. The sales figure stood at Rs. 4566.90 millions during the year-ago period.Net Profit for the quarter ended June 2025 zoomed to 486.80% from Rs. 170.40 millions to Rs. 999.90  millions.Operating Profit saw a handsome growth to 2390.00 millions from 1285.40 millions in the quarter ended June 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 5786.40 4566.90 26.70 5786.40 4566.90 26.70 16977.50 14867.10 14.20
Other Income 226.80 51.60 339.53 226.80 51.60 339.53 355.10 348.30 1.95
PBIDT 2390.00 1285.40 85.93 2390.00 1285.40 85.93 5220.60 4886.50 6.84
Interest 451.40 561.70 -19.64 451.40 561.70 -19.64 2202.40 574.20 283.56
PBDT 1938.60 723.70 167.87 1938.60 723.70 167.87 3018.20 4312.30 -30.01
Depreciation 376.00 455.50 -17.45 376.00 455.50 -17.45 1817.70 1023.90 77.53
PBT 1562.60 268.20 482.62 1562.60 268.20 482.62 1200.50 3288.40 -63.49
TAX 562.70 97.80 475.36 562.70 97.80 475.36 426.60 291.20 46.50
Deferred Tax 291.00 50.90 471.71 291.00 50.90 471.71 206.80 -285.20 -172.51
PAT 999.90 170.40 486.80 999.90 170.40 486.80 773.90 2997.20 -74.18
Equity 136.20 136.10 0.07 136.20 136.10 0.07 136.20 136.00 0.15
PBIDTM(%) 41.30 28.15 46.75 41.30 28.15 46.75 30.75 32.87 -6.44

Eris Lifesciences Share Price

1432.95 -13.55 (-0.94%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×